Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology

Clinical Lung Cancer

Volumn 8, Issue 3, 2006, Pages 214-216

  Achille, Mihaela ^a   Gallegos Ruiz, Marielle ^b   Giaccone, Giuseppe ^b   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bilirubin; Mediastinal lymph node; Monotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CLINDAMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GEMCITABINE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; BRONCHOSCOPY; BRONCHUS OBSTRUCTION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOBECTOMY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; LYMPHADENOPATHY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; OVERALL SURVIVAL; PARESTHESIA; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; SIDE EFFECT; SKIN TOXICITY; SMOKING; SQUAMOUS CELL CARCINOMA; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

EID: 33845398258     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.050     Document Type: Article

References (9)

1. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
2. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537.
3. Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 2005; 16:538-548.
4. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005; 23:3227-3234.
5. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:643-655.
6. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-144.
7. Tsao MS, Kamel-Reid S, Shepherd FA. Assessing EGFR mutations. N Engl J Med 2006; 354:527-528.
8. Giaccone G, Ruiz MG, Le Chevalier T, et al. Erlotinib for front-line treatment of advanced non-small-cell lung cancer. A phase II study. Clin Cancer Res. In press.
9. Clark GM, Cameron T, Das-Gupta A. Clinical benefit of erlotinib (Tarceva) in male smokers with squamous cell carcinoma. J Clin Oncol 2006; 24(18 suppl):405s (Abstract #7166).